Asco 2023 – a role for immuno-oncology in ovarian cancer at last?
Astra’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
The waxing and waning of the speedy approval
As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?
Finding the big spenders beyond big pharma
Developers like Vertex, Regeneron and Novo Nordisk have significantly upped R&D spending in recent years, and become important acquirers.
Big pharma holds steady on research spending
R&D spending by the world’s largest drug makers flatlined in 2022, with Roche footing the biggest bill and Astrazeneca the fastest accelerator.
Pfizer rescues biotech
The $43bn deal for Seagen marks the biggest biopharma acquisition since the pre-crash takeouts of Allergan and Celgene.